The Toll→NFκB Signaling Pathway Mediates the Neuropathological Effects of the Human Alzheimer's Aβ42 Polypeptide in Drosophila
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Alzheimer's (AD) is a progressive neurodegenerative disease that afflicts a significant fraction of older individuals. Although a proteolytic product of the Amyloid precursor protein, the Alphabeta42 polypeptide, has been directly implicated in the disease, the genes and biological pathways that are deployed during the process of Alphabeta42 induced neurodegeneration are not well understood and remain controversial. To identify genes and pathways that mediated Alphabeta42 induced neurodegeneration we took advantage of a Drosophila model for AD disease in which ectopically expressed human Alphabeta42 polypeptide induces cell death and tissue degeneration in the compound eye. One of the genes identified in our genetic screen is Toll (Tl). It encodes the receptor for the highly conserved Tl-->NFkB innate immunity/inflammatory pathway and is a fly homolog of the mammalian Interleukin-1 (Ilk-1) receptor. We found that Tl loss-of-function mutations dominantly suppress the neuropathological effects of the Alphabeta42 polypeptide while gain-of-function mutations that increase receptor activity dominantly enhance them. Furthermore, we present evidence demonstrating that Tl and key downstream components of the innate immunity/inflammatory pathway play a central role in mediating the neuropathological activities of Alphabeta42. We show that the deleterious effects of Alphabeta42 can be suppressed by genetic manipulations of the Tl-->NFkB pathway that downregulate signal transduction. Conversely, manipulations that upregulate signal transduction exacerbate the deleterious effects of Abeta42. Since postmortem studies have shown that the Ilk-1-->NFkB innate immunity pathway is substantially upregulated in the brains of AD patients, the demonstration that the Tl-->NFkB signaling actively promotes the process of Alphabeta42 induced cell death and tissue degeneration in flies points to possible therapeutic targets and strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Mutations in the APP protein which are associated with early onset of AD increase the production of Ab42 polypeptide or its tendency to form aggregates [7–10].”
BackgroundThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“The first AD-related mutations identified were in the amyloid b precursor protein (APP), a type I integral membrane protein [3–6].”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“The connection between APP and, in particular, the Ab42 polypeptide and AD was further strengthened by the finding that mutations in presenlin, a protease involved in the processing of the APP protein, are also associated with familial early onset AD [11–14].”
BackgroundCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“The connection between APP and, in particular, the Ab42 polypeptide and AD was further strengthened by the finding that mutations in presenlin, a protease involved in the processing of the APP protein, are also associated with familial early onset AD [11–14].”
BackgroundThe immune response of Drosophila
Hoffmann, J. A. (2003) · Nature · doi:10.1038/nature02021 · Cited by 1,553
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“play a beneficial rather than deleterious role [48,49,52].”
BackgroundSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · cited 1×
“Instead, recent studies have suggested that the large plaques may actually be relatively inert and that smaller oligomers of the Ab42 polypeptide correspond to the primary neurotoxic agent for AD [20–22].”
BackgroundCircuitry of nuclear factor κB signaling
Hoffmann, A., & Baltimore, D. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00375.x · Cited by 907
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734 · cited 2×
“However, while these studies clearly demonstrate that the inflammatory pathways are activated in the brains of AD patients, it is not clear from this correlation whether the deployment of these pathways actively promotes the process of neurodegeneration or whether they are functioning instead to retard the progression…”
BackgroundAnderson, K. V., Jürgens, G., & Nüsslein-Volhard, C. (1985) · Cell · doi:10.1016/0092-8674(85)90274-0 · Cited by 691
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Wilcock, G. K., & Esiri, M. M. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90155-1 · Cited by 608
Toll-like receptors — taking an evolutionary approach
Leulier, F., & Lemaitre, B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2303 · Cited by 581 · cited 1×
“Tl encodes a highly conserved type I transmembrane receptor that shares extensive homology with vertebrate receptors for the cytokines interleukin-1 (IL-1) and interleukin 18 (IL-18) [29,41,42].”
BackgroundRole of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease
Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schüffer, W., et al. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110455 · Cited by 543
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · cited 4×
“One of the first indications that it could contribute to disease progression came from epidemiological studies indicating that prolonged treatment with antiinflammatory drugs is correlated with a reduced risk of developing AD [57–59].”
BackgroundResultInfluentialHe, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
Schneider, D. S., Hudson, K. L., Lin, T. Y., & Anderson, K. V. (1991) · Genes & Development · doi:10.1101/gad.5.5.797 · Cited by 325 · cited 1×
“It is a hypomorphic mutation that has two amino acid substitutions in the extracellular domain of the receptor [46].”
BackgroundGenetic modifiers of tauopathy in Drosophila
Shulman, J. M., & Feany, M. B. (2003) · Genetics · doi:10.1093/genetics/165.3.1233 · Cited by 275
Cited by
Immunity in Drosophila melanogaster — from microbial recognition to whole-organism physiology
Buchon, N., Silverman, N., & Cherry, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3763 · Cited by 866
Toll‐like receptor 4 in CNS pathologies
Buchanan, M. M., Hutchinson, M., Watkins, L. R., & Yin, H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06736.x · Cited by 336
Cui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., & Lukiw, W. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178848 · Cited by 274
Petersen, A. J., Rimkus, S. A., & Wassarman, D. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110470109 · Cited by 139
Modeling the complex pathology of Alzheimer's disease in Drosophila
Fernandez-Funez, P., de Mena, L., & Rincon-Limas, D. E. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.013 · Cited by 69
“A subsequent screen of loss-of-function alleles identified Toll, a key receptor of the innate immunity pathway, as a suppressor of Aβ42 toxicity (Tan et al., 2008).”
Background
Metadata
- Authors
- Tan, L., Schedl, P., Song, H.-J., Garza, D., & Konsolaki, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-17
- Volume
- 3
- Issue
- 12
- Pages
- e3966
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2030419210
- Cited by
- 109
- References
- 21
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.